← Eichor
Condition: Multiple Myeloma Synced from ClinicalTrials.gov · July 27, 2026

Recruiting studies: Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07585760A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell
Phase 1 · 14 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07179679Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06246162Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Phase N/A · 1 location(s) · Boston Medical Center · NCT00898235Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Phase 2 · 1 location(s) · Larysa Sanchez · NCT06827860Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109323Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
Phase 2 · 2 location(s) · University College, London · NCT06762769Limited-duration Teclistamab
Phase 2 · 5 location(s) · Abramson Cancer Center at Penn Medicine · NCT05932680Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Phase N/A · 1 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06028087A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants
Phase 2 · 51 location(s) · GlaxoSmithKline · NCT07227311ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05632380A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409Helical Tomotherapy in Multiple Myeloma
NA · 1 location(s) · Fuling Zhou · NCT05970198Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
NA · 1 location(s) · University of Nebraska · NCT04898790Pre-malignant States to Hematologic Malignancies in Firefighters
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT06870760Myeloma Registry Platform (MYRIAM)
Phase N/A · 1 location(s) · iOMEDICO AG · NCT03308474Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms
EARLY_Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT07085559A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minima
Phase N/A · 1 location(s) · FengYan Jin · NCT06109233Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Phase N/A · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT00582621Sleep Apnea in Patients With MGUS and MM
Phase N/A · 1 location(s) · Michael Tomasson · NCT04114084Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Phase N/A · 7 location(s) · Dana-Farber Cancer Institute · NCT02269592AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/Phase 2 · 36 location(s) · AstraZeneca · NCT05850234LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NA · 4 location(s) · Nanjing Legend Biotech Co. · NCT07100067A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · 109 location(s) · Janssen Research & Development, LLC · NCT07258511Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT04888039A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Ref
Phase 1 · 5 location(s) · Hoffmann-La Roche · NCT06934044A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
NA · 1 location(s) · AC Camargo Cancer Center · NCT07268846European Myeloma Network (EMN) Sample Project
Phase N/A · 41 location(s) · European Myeloma Network B.V. · NCT06237803
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.